제약
Study in rats finds long-term omeprazole use disrupts mineral levels linked to anemia and bone health risks
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
Researchers in Brazil report that prolonged use of the proton pump inhibitor (PPI) omeprazole altered iron and calcium measures in adult rats and shifted how several minerals were distributed across organs—changes they say are consistent with higher risks of anemia and possible bone health harms. The authors and Brazil’s health regulator stress that PPIs remain effective for acid-related disorders, but warn against extended, unsupervised use.
Collegium Pharmaceutical, Inc. (COLL) held an investor conference call on March 19, 2026, to discuss its acquisition of AZSTARYS and relevant corporate subsidiaries from Corium Therapeutics. The deal aims to expand the company's position in the ADHD market. Executives including CEO Vikram Karnani joined the call.
AI에 의해 보고됨
Relmada Therapeutics, Inc. (RLMD) conducted its fourth quarter and full-year 2025 earnings conference call on March 19, 2026, at 4:30 PM EDT. The company released a press release detailing its business update and financial results for the periods ended December 31, 2025. Management highlighted forward-looking statements with associated risks.
Alkermes plc has published a slide deck accompanying its 2025 fourth-quarter earnings call. The materials were made available on February 25, 2026. This release provides insights into the company's financial performance for the period.
AI에 의해 보고됨
Sarepta Therapeutics, Inc. conducted its fourth quarter 2025 earnings call on February 25, 2026. The company released its financial results earlier that day, with details available on its website. Executives including CEO Douglas Ingram participated in the discussion.
Egypt's Minister of Health and Population Khaled Abdel Ghaffar met Kazakhstan's ambassador to Egypt, Askar Zhenis, to discuss strengthening bilateral cooperation in healthcare and pharmaceutical manufacturing technology. Abdel Ghaffar emphasized Egypt's interest in expanding ties through the transfer of pharmaceutical manufacturing technologies and harmonizing Good Manufacturing Practice standards. The talks covered collaboration in pharmaceutical production, biotechnology, and public health initiatives.
AI에 의해 보고됨
중국 바이오테크 기업 SciNeuro Pharmaceuticals가 스위스 제약 대기업 노바티스와 약 17억 달러 규모의 파트너십을 체결해 전 세계 5천5백만 명에게 영향을 미치는 알츠하이머병 치료제를 개발한다. 이 계약은 노바티스에게 진행성 뇌 질환에 대한 SciNeuro의 항체 후보 물질을 개발하고 상업화할 전 세계 독점권을 부여한다. SciNeuro의 신규 아밀로이드 베타 표적 항체 프로그램은 독점 혈뇌장벽 셔틀 기술을 활용해 알츠하이머 손상이 발생하는 뇌로 더 많은 약물이 통과하도록 돕는다.
Egypt steps up research cooperation with Takeda
2026년 03월 10일 18시 13분Roche shares decline after giredestrant trial fails endpoint
2026년 03월 05일 02시 11분Clara Foods develops world's first animal-free pepsin
2026년 03월 02일 08시 51분Egypt unveils integrated plan to boost pharmaceutical and garments exports
2026년 03월 01일 03시 28분Collegium Pharmaceutical publishes Q4 2025 earnings presentation
2026년 02월 17일 01시 32분Farmacias similares begins expansion to japan
2026년 02월 14일 10시 20분Egypt offers WHO-certified expertise to boost Africa's medicine production
2026년 02월 05일 16시 06분트럼프 할인 약 웹사이트 공개 후 일본 제약사 주가 하락
2026년 01월 30일 21시 57분Australian sepsis drug advances in human trial
2026년 01월 17일 13시 01분Delhi high court allows cheaper cancer drug in India